DETROIT – While most people are doing everything they can to avoid getting the coronavirus, some people are volunteering to be infected with it. They’re part of a movement pushing for challenge trials, research that would intentionally infect volunteers in order to speed up the development of an effective vaccine. READ: Emergency stay-in-place order issued for University of Michigan students to stop COVID-19 spreadIn a traditionally vaccine trial, volunteers receive either the vaccine or a placebo, then go about their usual lives. In a challenge trial, volunteers are directly exposed to the virus, speeding up the process -- but at a much greater risk. There would be 90 volunteers, ages 18 through 30 years old, who would be given tiny amounts -- by nose -- of COVID-19.

As of this report, there are 23 coronavirus vaccines being tested in humans. Researchers cannot deliberately expose people, so the vaccines are tested in places where the virus is circulating at higher levels in the community. Related: First COVID-19 vaccine tested in US poised for final testingIf a large number of participants are naturally exposed, researchers could have their answer fairly quickly. However, if that doesnt happen there are people signing up to step in and volunteer to become exposed. They are agreeing to participate in challenge trials.Right now, researchers believe they can test the virus vaccines without these challenge trials due to the number of hot spots around the country and world.

They said its vaccine induced antibody responses in all 45 participants in the first phase of testing. Related: First COVID-19 vaccine tested in US poised for final testingAccording to the New England Journal of Medicine, each participant received two vaccinations, 28 days apart. The researched said all participants developed neutralizing antibodies after the second dose. The study said antibodies were up to four times the amount found in patients who have recovered from COVID-19. Our vaccine generates neutralizing antibodies to levels that seem to be higher than what you get with a typical infection, said Dr. Tal Zaks, Moderna Chief Medical Officer.